Two trials have evaluated whether angiotensin receptor–neprilysin inhibitors (ARNIs) are associated with better cognitive function relative to an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker in participants with heart failure. The gene discussed is ACE; the disease is heart failure.